Sparrow Pharmaceuticals, Inc.
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies to address unmet needs in endocrinology and rheumatology. They focus on targeting the cellular biology of steroids, particularly through their proprietary HSD-1 inhibitors, to treat disorders caused by excess cortisol and autoimmune diseases, aiming to provide safer and more effective treatment options.
Industries
Nr. of Employees
small (1-50)
Sparrow Pharmaceuticals, Inc.
1050 SW 6th Avenue, Suite 1100, Portland, OR 97204
Patents
Products
Oral HSD-1 inhibitor (clinical candidate)
An oral small-molecule inhibitor of 11β-HSD1 designed to lower intracellular cortisol in target tissues to treat disorders of cortisol excess and to mitigate steroid-associated toxicities.
Fixed-dose combination: HSD-1 inhibitor + prednisolone (clinical candidate)
A fixed-dose combination program combining an HSD-1 inhibitor with prednisolone intended to maintain glucocorticoid efficacy while reducing systemic and tissue-specific steroid toxicities for autoimmune/inflammatory indications.
RESCUE (Phase 2 trial: ACTH-dependent Cushing’s syndrome)
International, multicenter Phase 2 study evaluating pharmacologic effects, efficacy, and safety of the HSD-1 inhibitor in ACTH-dependent Cushing’s syndrome, including target tissue cortisol assessments and clinical outcome measures.
ACSpire (Phase 2 study: Autonomous Cortisol Secretion)
Phase 2 study and open-label pilot evaluations of the HSD-1 inhibitor in patients with autonomous cortisol secretion due to adrenal lesions, assessing metabolic and endocrine morbidities associated with hypercortisolism.
PROST! (Phase 2 trial: HSD-1 inhibitor + prednisolone for polymyalgia rheumatica)
Multi-cohort Phase 2 study assessing whether co-administration of an HSD-1 inhibitor with prednisolone can maintain efficacy for polymyalgia rheumatica while reducing steroid-related toxicity; study expanded through multiple cohorts based on interim data.
DC-MACS (Investigator-led Phase 2 study collaboration in the UK)
Collaborative, investigator-led Phase 2 study conducted with academic partners to evaluate the HSD-1 inhibitor for autonomous cortisol secretion; company supplies investigational drug and placebo and supports study execution.
Oral HSD-1 inhibitor (clinical candidate)
An oral small-molecule inhibitor of 11β-HSD1 designed to lower intracellular cortisol in target tissues to treat disorders of cortisol excess and to mitigate steroid-associated toxicities.
Fixed-dose combination: HSD-1 inhibitor + prednisolone (clinical candidate)
A fixed-dose combination program combining an HSD-1 inhibitor with prednisolone intended to maintain glucocorticoid efficacy while reducing systemic and tissue-specific steroid toxicities for autoimmune/inflammatory indications.
RESCUE (Phase 2 trial: ACTH-dependent Cushing’s syndrome)
International, multicenter Phase 2 study evaluating pharmacologic effects, efficacy, and safety of the HSD-1 inhibitor in ACTH-dependent Cushing’s syndrome, including target tissue cortisol assessments and clinical outcome measures.
ACSpire (Phase 2 study: Autonomous Cortisol Secretion)
Phase 2 study and open-label pilot evaluations of the HSD-1 inhibitor in patients with autonomous cortisol secretion due to adrenal lesions, assessing metabolic and endocrine morbidities associated with hypercortisolism.
PROST! (Phase 2 trial: HSD-1 inhibitor + prednisolone for polymyalgia rheumatica)
Multi-cohort Phase 2 study assessing whether co-administration of an HSD-1 inhibitor with prednisolone can maintain efficacy for polymyalgia rheumatica while reducing steroid-related toxicity; study expanded through multiple cohorts based on interim data.
DC-MACS (Investigator-led Phase 2 study collaboration in the UK)
Collaborative, investigator-led Phase 2 study conducted with academic partners to evaluate the HSD-1 inhibitor for autonomous cortisol secretion; company supplies investigational drug and placebo and supports study execution.
Services
End-to-end clinical development services for Phase 1–2 programs including study design, site management, patient recruitment, data collection, and interim analysis for endocrine and rheumatology indications.
Provisioning of investigational HSD-1 inhibitor compound and matched placebo to support investigator-initiated and collaborative clinical trials.
Regulatory affairs planning, interactions with health authorities, and implementation of quality management systems to support clinical development and regulatory submissions.
End-to-end clinical development services for Phase 1–2 programs including study design, site management, patient recruitment, data collection, and interim analysis for endocrine and rheumatology indications.
Provisioning of investigational HSD-1 inhibitor compound and matched placebo to support investigator-initiated and collaborative clinical trials.
Regulatory affairs planning, interactions with health authorities, and implementation of quality management systems to support clinical development and regulatory submissions.
Expertise Areas
- Clinical trial management
- Translational pharmacology
- Steroid biology and HSD-1 therapeutics
- Small-molecule drug development
Key Technologies
- HSD-1 (11β-HSD1) inhibition
- Oral small-molecule therapeutics
- Fixed-dose combination therapy (HSD-1 inhibitor + glucocorticoid)
- Intracellular biomarker assays (tissue-specific cortisol measurement)
News & Updates
Sparrow Pharmaceuticals is collaborating on a Phase 2 clinical study in the UK of clofutriben (SPI-62) for the treatment of autonomous cortisol secretion (ACS). The study is led by researchers from Oxford and Sheffield and aims to evaluate the efficacy and safety of clofutriben in treating ACS.
Sparrow will present interim data from its Phase 2 trial of clofutriben with prednisolone for PMR at the ACR 2024 conference. The trial has been expanded to a fifth cohort based on encouraging results.
The Phase 2 RESCUE trial of clofutriben for endogenous Cushing’s syndrome is complete. Clofutriben has received FDA Orphan Drug Designation for this indication.
The first patient has been dosed in the Phase 2 ACSpire study of SPI-62 for the treatment of autonomous cortisol secretion (ACS).
The Phase 2 trial of SPI-62 with prednisolone for PMR has been expanded to include a third cohort to further evaluate its efficacy and safety.
The first patient has enrolled in the open-label extension phase of the RESCUE trial for SPI-62 in ACTH-dependent Cushing’s syndrome, to assess long-term safety and efficacy.
Sparrow Pharmaceuticals is collaborating on a Phase 2 clinical study in the UK of clofutriben (SPI-62) for the treatment of autonomous cortisol secretion (ACS). The study is led by researchers from Oxford and Sheffield and aims to evaluate the efficacy and safety of clofutriben in treating ACS.
Sparrow will present interim data from its Phase 2 trial of clofutriben with prednisolone for PMR at the ACR 2024 conference. The trial has been expanded to a fifth cohort based on encouraging results.
The Phase 2 RESCUE trial of clofutriben for endogenous Cushing’s syndrome is complete. Clofutriben has received FDA Orphan Drug Designation for this indication.
The first patient has been dosed in the Phase 2 ACSpire study of SPI-62 for the treatment of autonomous cortisol secretion (ACS).
The Phase 2 trial of SPI-62 with prednisolone for PMR has been expanded to include a third cohort to further evaluate its efficacy and safety.
The first patient has enrolled in the open-label extension phase of the RESCUE trial for SPI-62 in ACTH-dependent Cushing’s syndrome, to assess long-term safety and efficacy.